NCT02020226View on ClinicalTrials.gov

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Solid Tumors
Interventions
DRUG

TH-302

480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle

Trial Locations (2)

85364

Yuma Regional Cancer Center, Yuma

85719

The University of Arizona Cancer Center, Tucson

Sponsors
All Listed Sponsors
lead

Threshold Pharmaceuticals

INDUSTRY